Description of Adcetris (Brentuximab Vedotin)
Adcetris (Brentuximab Vedotin) is the first approved CD-30 directed antibody drug conjugate. Adcetris contains the active substance brentuximab vedotin, an anti-cancer agent, which is made up of a monoclonal antibody linked to a substance intended to kill cancer cells.
Its use and indications
Adcetris® (Brentuximab Vedotin) injection for intravenous infusion is indicated for the treatment of:
- Hodgkins Lymphoma after failure of autologous stem cell transplant (ASCT)
- Hodgkins Lymphoma in patients who are not ASCT candidates after failure of at least 2 multiagent chemotherapy regimens
- Systemic anaplastic large cell lymphoma after failure of at least 1 multiagent chemotherapy regimen
Treatment related info
For treatment related information, please consult your treating Physician.
Adcetris powder for infusion 50 mg vial
Storage and handling
Store at 2°- 8° C, do not freeze.
How do we source the Drug?
Super Specialities Pharma -India will assist in sourcing the drug through its efficient network, across the globe, and ensure the delivery is prompt. However, a valid prescription from the treating Oncologist is mandatory, with all relevant documents associated with its procurement is essential.
Company that Manufactures/ Markets:
M/s Seattle Genetics, Inc
Contact Details :
Mob. Nos: +91 7738100125, +91 7738151650
E Mail: email@example.com